Podcasts about moffitt cancer center

Prof Claire Harrison from Guy's and St Thomas' NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.

In today's episode, the discussion features Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), drawing on efficacy and safety findings from the phase 3 COMPETE trial (NCT03049189). 

Join host Dr. Nikolaos Papadantonakis as he welcomes Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center to discuss the fundamentals of allogeneic hematopoietic stem cell transplantation for MDS patients.  Our experts break down complex medical concepts into easy-to-understand language, helping patients make informed decisions about this important treatment option.

In this follow-up episode,  Dr. Nikolaos Papadantonakis continues the conversation with Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center, diving deeper into advanced transplant topics. This episode is ideal for patients and families who want to understand the nuances of transplant care and post-transplant management.

Dr. Olga Klinkova, Infectious Diseases Clinician at the Moffitt Cancer Center and Research Institute, presents a talk on Candida Infections. Dr. Klinkova begins by discussing the epidemiology of Candida. She then touches upon the importance of biofilms on the pathogenicity of Candida strains. Next, she breaks down the individual Candida species and highlights unique characteristics of each one. Following this, she presents several unique cases of human Candida infections and through the cases, highlights Candida auris, oropharyngeal candidiasis, esophageal disease, and candidemia. Lastly, she closes with information on hepatosplenic candidiasis.

In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Michael Silverstein, Managing Partner of Healthcare IT & Life Sciences, DRI and Kamal Jethwani, MD, Co-Founder, Decimal.health and VP, Digital Ventures, Moffitt Cancer Center. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

On this episode Justin Barnes records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Nainesh Parikh, MD, MBA, VP, Chief Clinical Expansion & Partnerships Officer at Moffitt Cancer Center, and Rich Scarfo, President at HLTH, Inc. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

La Dra. Isabel Matilde Chinchía, Hematóloga y Oncóloga Clínica del Grupo de Linfomas de la ACHO en Colombia, en conjunto con el Dr. José Sandoval, Hematólogo Oncólogo del MOFFITT Cancer Center en Estados Unidos, compartieron las actualidades en linfoma no Hodgkin (LNH) B difuso de células grandes.Su intervención se llevó a cabo durante el 9° Congreso Nacional de Actualización en Hematología y Oncología de la ACHO, realizado del 14 al 16 de noviembre de 2025 en Cartagena de Indias, Colombia.Fecha de grabación: 15 de noviembre de 2025 Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso. Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

12 proven business models that separate successful products from failures!Product Manager Brian Orlando & Enterprise Business Agility Consultant Om Patel examine 12 real-world business models with real examples of the companies that employ them!Based on "The Art of Profitability" by Adrian Slywotzky (2002), this part-1-of-2 podcast covers:• Customer Solution Model (Palantir, SAP, Salesforce)• Product Pyramid (Apple, Tesla, GM)• Multi-Component Pricing (Uber, Coca-Cola)• Switchboard Platforms (Uber, Airbnb, eBay)• Time & Materials (Consulting firms)• Blockbuster Model (Pharma, Netflix)• Profit Multiplier (Microsoft, Disney)• Entrepreneurial Model• Specialist Model (Mayo Clinic, Agile Coaches)• Installed Base (Printers, Razors, K-Cups)• De Facto Standard (Windows, Adobe PDF)• Brand Model (Apple, Nike, BMW)Perfect for product managers, agile coaches, startup founders, and business leaders trying to understand which revenue model fits their product strategy.

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Gregorio Uglioni sits down with senior customer experience manager Patty Soltis to explore the intricate dynamics of convincing the C-suite to embrace customer experience initiatives. Patty shares invaluable insights on aligning CX efforts with business strategies, understanding executive priorities, and demonstrating the true value of CX to drive profitability. This episode is a must-listen for anyone looking to bridge the gap between customer experience and executive buy-in. About Patty Soltis Over three decades of experience, Patty has been a practitioner, consultant, and analyst in CX. She led dysfunctional organizations through change management to profitability. She found significant financial benefits with more profitable sales and lower expenses using the CX discipline. Using customer-centric business strategies, Patty created customer centric cultures, advised organizations to adopt CX, and analyzed CX best practices. Patty started her career listening to the voice of the employee, learning more about the customer elevating customer experiences. Patty serves as a senior customer experience manager at Upwork. Patty was a principal analyst – CX for eMarketer/Insider Intelligence and a patient experience consultant for Moffitt Cancer Center. She was a consultant for several years working with both small and enterprise organizations. Patty worked in retail for 27 years. She was a VP/GM for Neiman Marcus, Marshall Fields, and Lord & Taylor. Patty is a CCXP, CX-PRO and was named a CX Influencer by CX Network in 2024 and CX Scoop in 2023. She is an active member of the CXPA where she led the writing of the Book of Knowledge, launched the FL CXPA network, serves as a leader on the FL network and the Regional Council. Patty is a member of Horizon CX Board of Advisors. Resources  Upwork: https://www.upwork.com/ Please, hit the follow button and leave your feedback: Apple Podcast: https://www.cxgoalkeeper.com/apple Spotify: https://www.cxgoalkeeper.com/spotify Follow Gregorio Uglioni on Linkedin: https://www.linkedin.com/in/gregorio-uglioni/ Gregorio Uglioni is a seasoned transformation leader with over 15 years of experience shaping business and digital change, consistently delivering service excellence and measurable impact. As an Associate Partner at Forward, he is recognized for his strategic vision, operational expertise, and ability to drive sustainable growth. A respected keynote speaker and host of the well-known global podcast Business Transformation Pitch with the CX Goalkeeper, Gregorio energizes and inspires organizations worldwide with his customer-centric approach to innovation.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Part 2 - Neville James is joined by Paul Blair and Kurt Schindler as they host a big Halloween bash from October 29 to November 2 at Bungalows on the Bay, featuring live bands, a haunted house, friendly family events, trunk or treat. Fundraiser to benefit Moffitt Cancer Center in Florida.

Every high-performing business has one thing in common: reliability. Hospitals cannot afford mistakes. Neither can you. In this episode of Beyond The Claim, Vince Perri sits with Anay Moscu, PharmD, BCPS, BCOP, ACRP-CP, Director of Pharmacy for Outpatient Infusion Centers at Moffitt Cancer Center, to uncover the systems that literally save lives and show how you can use them to scale your company faster. What you will learn: • The Stop Error Stack: how hospitals eliminate million-dollar mistakes • Why every business needs independent checks and hard stops • The Empathy with Accountability formula for leading under pressure • How to design checklists people actually follow • AI tools hospitals use today that you can apply to your business Chapters: 00:00 Intro: Checklists That Save Lives 01:52 What Oncology Pharmacy Really Does 05:40 How Clinical Trials and Infusion Workflows Operate 09:28 The Stop Error Stack: Eliminating Mistakes 13:35 Clean Rooms, Barcoding, and Validation 17:10 Building Systems That People Actually Follow 21:22 Hiring For Detail And Team Fit 26:45 Balancing Empathy With Accountability 32:12 Getting Buy-In Across Teams 37:44 AI And Automation In Modern Pharmacy 42:55 Translating Hospital Systems To Business Growth 48:05 Life Advice: Be Present And Give Yourself Grace 52:00 Outro And Free Checklist Guest Contact Links

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.---This podcast is supported by:Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care.---TIMESTAMPS0:00 - Introduction02:20 - Case 1 (Incidental Renal Mass)16:52 - Case 2 (Bilateral Renal Masses)37:22 - Case 3 (Locally Advanced Renal Mass)56:34 - Case 4 (Symptomatic, Metastatic Disease)01:14:00 - Final Takeaways

In today's episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.   In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.

In this episode, we explore Carthera, a French biotech company developing novel ultrasound-based technologies to improve drug delivery to the brain. Based in Paris and spun out from academic research, Carthera is best known for its implantable device, SonoCloud, which uses low-intensity pulsed ultrasound to temporarily open the blood-brain barrier. This allows for increased drug penetration into brain tumors, addressing one of the major challenges in treating diseases like glioblastoma. This episode features leadership and key collaborators from Carthera, including CEO Frédéric Sottilini, who shares how his background in therapeutic ultrasound and medical device development helped guide the company's path from concept to clinical trials. We are also joined by Professor Alexandre Carpentier, MD, PhD, the neurosurgeon who founded Carthera, and Michael Vogelbaum, MD, PhD, Chief of Neurosurgery at Moffitt Cancer Center, who offers his perspective as a clinical investigator working with the company's technology. This episode offers insight into the intersection of engineering, neurosurgery, and translational research, and the collaborative effort required to develop new treatment tools for brain tumor patients. Learn more at https://carthera.eu/ This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

In today's episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.  In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL. 

This episode features Joanna Weiss, Executive Vice President and CFO at Moffitt Cancer Center, who shares her journey through finance and revenue cycle leadership. She discusses key priorities including financial stabilization, strategic growth, AI-driven automation, and how the CFO role is evolving to support long-term innovation and patient-centered care.

Terms like hospice and palliative care can instantly make us think of worst case scenarios, but whether you are a patient or a caregiver, they should be considered a normal part of the experience offered by experts in Supportive Care Medicine. Treating a patient is not just about killing the cancer, but doing everything you can to improve their quality of life, a subject that Dr. Saima Rashid is familiar with as a specialist in palliative care, and Parmvir as a caregiver to her sister Sukhneil. Join us to learn more about how and when to request services, and the benefits that they offer. Find out about the work being done by Moffitt's Department of Supportive Care Medicine and how they can help you: https://www.moffitt.org/treatments/supportive-care-medicine/ Learn more about our guests: Dr. Saima Rashid: https://www.moffitt.org/providers/saima-rashid/ Dr. Parmvir Bahia: parmvir.com Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

In a conversation with CancerNetwork® at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference, Tiba Al Sagheer, PharmD, BCOP, BCACP; Rebecca Gonzalez, PharmD, BCOP, FASTCT; and Syeda Saba Kareem PharmD, BCOP, spoke about their presentations on managing adverse effects (AEs) across different hematologic malignancy populations. At the meeting, Al Sagheer, Gonzalez, and Kareem presented their ideas for treating patients with lymphoma, leukemia, and multiple myeloma, respectively. Al Sagheer is a Pharmacy Quality Improvement Coordinator and Transplant/Cellular Therapy and Hematology Clinical Pharmacy Specialist at Miami Cancer Institute of Baptist Health South Florida. Gonzalez is a clinical pharmacy specialist in Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center. Kareem is a clinical pharmacy supervisor in Malignant Hematology at Moffitt Cancer Center. Across different disease states, the presenters outlined the most common toxicities associated with CAR T-cell therapy, bispecific antibodies, and other novel immunotherapies. Additionally, they described strategies for reducing the severity of AEs such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome as well as other oral, dermatological, and nail toxicities. Other key considerations for preserving quality of life among those receiving cellular therapy included risk stratifying patients based on tumor burden and inflammatory markers at baseline to inform prophylactic measures. Each presenter shared key takeaways for treating patients who experience treatment-related AEs based on their individual presentations. Al Sagheer emphasized that it is not “one size fits all” when it comes to therapy, as providers must tailor their use of specific drugs, prophylactic measures, and anti-infective medication to each individual patient. Kareem noted that cellular therapy represents an evolving field, as toxicity mitigation strategies will continue to change over time as new data emerge. Finally, Gonzalez underscored the intimate nature of the cellular therapy field, which presents opportunities to collaborate with other institutions and receive guidance on managing complex cases.  References Al Sagheer T. Mastering the management of adverse effects from cellular therapies in lymphoma. Presented at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL. Gonzalez R. Navigating the challenges: managing adverse effects of cellular therapies in ALL. Presented at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL. Kareem SS. Management of adverse events of CAR-T and T-cell engagers in myeloma. Presented at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL.

Cancer is a profoundly disabling illness, whether that is due to side effects from the life-saving treatments or the disease itself. Understandably then, patients need constant and vital support in the form of caregivers, but who do we consider to be a caregiver, and what does their role involve? In this episode we discuss the essential role of caregivers, who qualifies as a caregiver, and the responsibilities they take on. We also address an important question: who looks after the caregivers when they themselves are impacted? Join us as we uncover the challenges and rewards of caregiving in the context of cancer, and highlight the importance of support for those who give so much to others. Learn more about our guests: Mr. Travis Coy: https://www.linkedin.com/in/travis-j-coy Dr. Parmvir Bahia: parmvir.com Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, Engagement, and Equity at Moffitt Cancer Center and Artha Science Media. Follow COEE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions. Key topics discussed included: • The importance of ruling out secondary causes of erythrocytosis in PV patients. • The role of JAK2 mutation testing and EPO levels in diagnosis of PV. • Treatment options for PV, including phlebotomy, hydroxyurea, and interferon, as well as the emerging role of ruxolitinib. • Risk stratification in ET and the significance of driver mutations like JAK2, CALR, and MPL. • The management of acquired von Willebrand disease in patients with high platelet counts. • Insights from Dr. Kuykendall's recent ASCO plenary presentation on the VERIFY Study and the potential of resveratide in PV treatment. Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!  

On this episode you'll hear from caregivers and advocates about how they face this challenge. Our guests are Rachel Piltch-Loeb, author of The Millennial Caregiver: Caring for Loved Ones in the Busiest Years of Your Life. Viviam Sifontes, research educator at Moffit Cancer Center Lauren Klinger, a Wesley Chapel resident and writer. She's been a caregiver and is author of the “Learn from My Mistakes” Substack. Thanks to our partners in developing this show - Moffitt Cancer Center in Tampa and the Alzheimer's Association, Florida region. This Caregiving project was funded by a grant from WETA and Vu Haus. It's part of a new documentary and national engagement campaign on the state and stakes of providing care in America. A feature-length documentary and accompanying short films are available on PBS.org and at Well Beings. 

On this episode you'll hear from caregivers and advocates about how they face this challenge. Our guests are Rachel Piltch-Loeb, author of The Millennial Caregiver: Caring for Loved Ones in the Busiest Years of Your Life. Viviam Sifontes, research educator at Moffit Cancer Center Lauren Klinger, a Wesley Chapel resident and writer. She's been a caregiver and is author of the “Learn from My Mistakes” Substack. Thanks to our partners in developing this show - Moffitt Cancer Center in Tampa and the Alzheimer's Association, Florida region. This Caregiving project was funded by a grant from WETA and Vu Haus. It's part of a new documentary and national engagement campaign on the state and stakes of providing care in America. A feature-length documentary and accompanying short films are available on PBS.org and at Well Beings. 

Dr. Robert Castro, Infectious Diseases Clinician at the Moffitt Cancer Center and Research Institute, presents this review on infections associated with vector-borne and zoonotic exposures. Dr. Castro begins by discussing vector -borne infections, dividing them into mosquito-borne and tick-borne diseases. Syndromes discussed include Dengue, Chikyunguna, West Nile Virus, and Japanese Encephalitis. Next, Zoonotic infections such as Rabies Virus, Hantavirus, Orf virus, and B virus are covered. Dr. Castro closes by discussing vector control strategies.

ABOUT THIS EPISODENeuroendocrine cancer care typically involves a multidisciplinary team which sometimes involves an Advanced Practice Provider (APP). In this episode, Moffitt Physician Assistant Tiffany Valone clarifies the role of an APP in neuroendocrine cancer.TOP TEN QUESTIONS What is a NP/PA/APP? -Are you a doctor? How are you different from or similar to a doctor? - How is your role similar to or different from a nurse practitioner? How did you enter the neuroendocrine cancer or NET world? How did you learn about neuroendocrine cancer? Could you be considered a NET expert? What is your role in the neuroendocrine cancer world? What is your role with your medical team? If I go to your institution to see a neuroendocrine cancer expert, how is it determined which provider I will see?If I see you (or another NP/PA), would I also see a doctor? If yes, when/how? If not, why/why not and how does this work? What does a “team approach” mean?Who goes over scan results? Is this something you can do?Who orders my scans and treatments?If I have a question or concern, who do I communicate with and what's the best way to communicate?How are your recommendations communicated with someone's local oncologist?What advice do you have for patients when they receive differing opinions?*Bonus: How do you continue to learn and keep up to date with neuroendocrine cancer? What recommendations would you have for patients who would like to encourage their local oncologists or APPs to learn about neuroendocrine cancer?ABOUT TIFFANY VALONETiffany Valone is a Physician Assistant and Manager of the GI and Senior Adult Advanced Practice Providers at Moffitt Cancer Center in Tampa, FL. She started her career at Moffitt in 2006 in GI medical oncology focusing on treating patients with colorectal and pancreaticobiliary cancers. A few years into her career she joined Dr. Jonathan Strosberg to help with his growing neuroendocrine practice.  For the past 16 years she has been an integral provider within this multidisciplinary team.  She was awarded Moffitt's Advanced Practice Provider of the Year in 2012 and the North American Neuroendocrine Tumor Society's AHP/APP of the Year in 2024. She is also a member of Moffitt's APP Professional Clinical Ladder Executive Committee and spearheads Moffitt's APP Grand Rounds lecture series. She has a passion for teaching and mentoring new providers in the NET field. She has given presentations on NETs and other GI malignancies at both state and national conferences. In her spare time, she enjoys traveling with her husband and three children or relaxing at the beach.  For more information, visit https://www.ncf.net/podcast/46For more information, visit NCF.net.

Dr. Olga Klinkova, Assistant Professor at the USF Morsani College of Medicine, and Transplant ID Associate at Moffitt Cancer Center, presents this board review lecture on CMV infections in immunocompromised stem cell transplant recipients. Topics covered include the epidemiology of CMV infection, CMV pneumonitis, CMV GI disease, CMV diagnosis, CMV treatment post-transplant, resistant CMV infection, and CMV prophylaxis options, Interactive questions are included within the presentation.

This week, Steph & Ash keep the Tampa Bay Tech PoweredUp series rolling with a fun and insightful chat with Doug Fee, Chief Information Security Officer at Moffitt Cancer Center. We explore the complex tech challenges facing the healthcare world, including the vital role cybersecurity plays in protecting patients and their data. Doug also breaks […] The post Bold Moves in Healthcare Tech with Moffitt’s CISO appeared first on Radio Influence.

This week, Steph & Ash keep the Tampa Bay Tech PoweredUp series rolling with a fun and insightful chat with Doug Fee, Chief Information Security Officer at Moffitt Cancer Center. We explore the complex tech challenges facing the healthcare world, including the vital role cybersecurity plays in protecting patients and their data. Doug also breaks […] The post Bold Moves in Healthcare Tech with Moffitt's CISO appeared first on Radio Influence.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

June is recognized in the US as Caribbean-American Heritage Month. So what better time to say Sante! or Cheers! to recognize the important achievements of researchers working to support members of the Caribbean community. We speak with Dr. Dorothie Durosier Mertilus about how important it is it literally be able to speak someone's language; in her case French or Haitian Creole. We hear from from Dr. Clement Gwede, the scientist whose lab is out in the community. Coming at gaps in care from different angles means that patients can be supported in meaningful ways, to offer them the best outcomes. Learn more about our guests: Dr. Dorothie Durosier Mertilus, and Dr. Clement Gwede. Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

My team at Moffitt Cancer Center helped save my life and I'm forever grateful for their brilliance, dedication, and friendship over the past 6+ years. This is a repost of the episode I did with them last year.  Being a guest on the PEP Talks podcast for providers and staff at Moffitt was an honor, a privilege, and a labor of love. Moffitt is an amazing place filled with amazing people dedicated to curing cancer.Side note: I know I've been off the radar for a couple of years -- life's been challenging and busy and full of good things. Meanwhile, in addition to my full-time job, I'm writing a book about dealing with cancer, developing public speaking opportunities, and working on arrangements for the apartment we just bought in Italy. It's been a lifelong dream and we're so excited! I'll do an episode about this in the not-to-distant-future, so you can come along for that process, as well. It's all part of the "etc." in "Life, Cancer, Etc."Keywords: Moffitt, H. Lee Moffitt Cancer Center, cancer diagnosis, sarcoma, cancerNote: I'm not a medical professional. Everyone in these podcasts is sharing their own experiences.You can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtcYou can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtc

Send us a textIn this episode of the 'Midlife with Courage' podcast, host Kim welcomes the magical Kimmie Sue Hall. They discuss Kimmie Sue's life in Orlando, Florida, her courageous journey helping a friend overcome alcoholism, her retirement from a 30-year career with Disney, and the personal trials faced when her son battled cancer. She also shares some glimpses into her role as the wife of a rockstar and how the unexpected end of REO Speedwagon changed how she saw her future playing out. The episode highlights themes of courage, family, and authenticity while sharing inspiring anecdotes about making dreams come true at Disney and providing support during challenging times. Kimmie Sue also shares plans for a meaningful upcoming concert and her son's involvement in cancer awareness and support. 00:00 Introduction to Midlife with Courage00:21 Meet Kimmie Sue Hall01:29 A Courageous Conversation04:46 Kimmie Sue's Magical Career at Disney12:49 Tommy's Battle with Cancer17:58 Facing the Unthinkable: A Mother's Strength18:44 Raising Awareness: Testicular Cancer19:38 Miracles and Mentorship20:18 Foundations and Family Support23:42 A New Chapter: College and Music26:02 A Farewell Concert for a Cause33:11 Final Thoughts and Messages"Courage is a very contagious thing." Dr. Philippe Spiess of Moffitt Cancer Center in Tampa Florida. If you would like to support the Moffitt Cancer Center through a donation, please go to this link: https://fundraise.moffitt.org/campaign/651751/donateSupport the showKim Benoy is a retired RN, Certified Aromatherapist, wife and mom who is passionate about inspiring and encouraging women over 40. She wants you to see your own beauty, value and worth through sharing stories of other women just like you.Would you like to get a "sneak" listen to each podcast? Subscribe to my website to get my weekly inspirational message and a link to that week's podcast a day ahead of everyone else! Just click the link below to get on the list! SUBSCRIBE WEBSITEFACEBOOK

Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer. --- TIMESTAMPS 00:00 - Introduction 05:40 - Patient Selection Criteria 09:49 - Workflow 19:17 - Procedure Timing and Coordination 29:39 - Challenges and Considerations in Drug Dosing 32:39 - Optimizing Treatment Cycles and Patient Response 37:56 - Managing Post-Treatment and Adverse Effects 43:43 - Future Research and Gaps in Current Interventions 50:45 - Exploring New Applications for PHP Therapy 55:02 - Conclusion --- RESOURCES Hepzato: https://hepzatokit.com/ FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study: https://pubmed.ncbi.nlm.nih.gov/38704501/ FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A): https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510 Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial: https://pubmed.ncbi.nlm.nih.gov/36624292/ Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/ Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/ Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/ Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases: https://pubmed.ncbi.nlm.nih.gov/38587534/

Research is so critical to the field of surgery worldwide. But how does the world of academic surgery compare in the UK? Join BTK fellow Jon Williams and ASGBI partner Jared Wohlgemut  for another installment of our BTK/ASGBI collaborative series where we take a deep dive investigating the many facets of surgical research–everything from getting started, funding, collaboration, mentorship, and sage advice from two incredibly successful academic surgeons. Professor Susan Moug represents the UK while Dr. Lesly Dossett represents the US in this excellent episode for any trainee or surgeon who is academically-inclined. After listening, you get to decide–who does it better?? UK or US? Professor Moug is an Honorary Professor at the University of Glasgow, Scotland. She is a Consultant Colorectal and Robotic surgeon at Golden Jubilee National University Hospital in Clydebank, and at the Royal Alexandra Hospital in Paisley, Scotland. She is also the Director of Research for the Association of Surgeons of Great Britain and Ireland since 2021, and the Surgical Specialty Lead for Colorectal Research at the Royal College of Surgeons of England. She has been awarded a Senior Fellowship from the Chief Scientist Office of the Scottish Government, and was the chief investigator for the Emergency Laparotomy in Frailty multicentre study, and the No-Laps follow-on study. Essentially, she is one of the leading researchers in emergency surgery in the UK, having been awarded over 1 million in grant funding for this under-researched and underfunded area. Dr. Dossett is an associate professor and surgical oncologist at the University of Michigan. After completing her undergraduate degree at Western Kentucky University, She completed both medical school and her general surgery residency at Vanderbilt University in Nashville, TN, during which she obtained an Agency for Healthcare Research and Quality training grant as well as a Masters in Public Health during research time. Following residency, she served as an active duty staff surgeon in the US Navy for several years before pursuing surgical oncology fellowship training at Moffitt Cancer Center. In 2016 she came on to University of Michigan as faculty and has since held numerous academic leadership roles both institutionally and nationally, including vice chair for faculty development, chief of the division of surgical oncology, and president of the Surgical Outcomes Club. Dr. Dossett has an impressive portfolio of research work focusing on implementation and de-implementation of comprehensive cancer care, which is funded through multiple NIH grants.  If you enjoyed this episode, stay tuned for more upcoming BTK/ASGBI collaborative content. If you have any questions or comments, please feel free to reach out to us at hello@behindtheknife.org.  ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing

Scientists are using the power of mathematics to take action against cancer. These unique analytical methods have contributed to an exciting new approach to cancer investigation and treatment. Joining us on this episode is Dr. Alexander (Sandy) Anderson, Ph.D. Dr. Anderson is the Chair of Integrated Mathematical Oncology at Moffitt Cancer Center. Dr. Anderson researches the mathematical modeling of cancer in order to develop eco-evolutionary therapies that can control cancer – rather than eradicate it.  Listen in to learn about: The “dialogue” between a growing tumor and its changing environment. How scientists are using mathematics to understand complex biological phenomena. What it takes to construct mathematical models that translate to cancer treatment strategies. Is mathematical modeling the future of cancer research? Find out now from a professional at the forefront of this investigative approach. To find out more about Dr. Anderson and his work, visit www.mathematical-oncology.org and www.moffitt.org. Upgrade Your Wallet Game with Ekster!  Get the sleek, smart wallet you deserve—and save while you're at it! Use coupon code FINDINGGENIUS at checkout or shop now with this exclusive link: ekster.com?sca_ref=4822922.DtoeXHFUmQ5  Smarter, slimmer, better. Don't miss out! Episode also available on Apple Podcast: http://apple.co/30PvU9C